These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8625645)

  • 1. Is it time to reposition vasopressors and inotropes in sepsis?
    Rudis MI; Basha MA; Zarowitz BJ
    Crit Care Med; 1996 Mar; 24(3):525-37. PubMed ID: 8625645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressors and Inotropes in Sepsis.
    Stratton L; Berlin DA; Arbo JE
    Emerg Med Clin North Am; 2017 Feb; 35(1):75-91. PubMed ID: 27908339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.
    Jentzer JC; Coons JC; Link CB; Schmidhofer M
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):249-60. PubMed ID: 25432872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressors During Sepsis: Selection and Targets.
    Gelinas JP; Russell JA
    Clin Chest Med; 2016 Jun; 37(2):251-62. PubMed ID: 27229642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome.
    Hayes MA; Timmins AC; Yau EH; Palazzo M; Watson D; Hinds CJ
    Crit Care Med; 1997 Jun; 25(6):926-36. PubMed ID: 9201043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].
    Ertmer C; Sielenkämper AW; van Aken H; Bone HG; Westphal M
    Anaesthesist; 2005 Apr; 54(4):346-56. PubMed ID: 15625598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concomitant use of ultra short beta-blockers with vasopressors and inotropes in critically ill patients with septic shock: A systematic review and meta-analysis of randomized controlled trials.
    Al Sulaiman K; Alkofide HA; AlFaifi ME; Aljohani SS; Al Harthi AF; Alqahtani RA; Alanazi AM; Nazer LH; Al Shaya AI; Aljuhani O
    Saudi Pharm J; 2024 Jun; 32(6):102094. PubMed ID: 38812943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.
    Oba Y; Lone NA
    J Crit Care; 2014 Oct; 29(5):706-10. PubMed ID: 24857641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study.
    Yu M; Levy MM; Smith P; Takiguchi SA; Miyasaki A; Myers SA
    Crit Care Med; 1993 Jun; 21(6):830-8. PubMed ID: 8504649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials.
    Belletti A; Castro ML; Silvetti S; Greco T; Biondi-Zoccai G; Pasin L; Zangrillo A; Landoni G
    Br J Anaesth; 2015 Nov; 115(5):656-75. PubMed ID: 26475799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proarrhythmic effects of intravenous vasopressors.
    Tisdale JE; Patel RV; Webb CR; Borzak S; Zarowitz BJ
    Ann Pharmacother; 1995 Mar; 29(3):269-81. PubMed ID: 7606074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality.
    Tarvasmäki T; Lassus J; Varpula M; Sionis A; Sund R; Køber L; Spinar J; Parissis J; Banaszewski M; Silva Cardoso J; Carubelli V; Di Somma S; Mebazaa A; Harjola VP;
    Crit Care; 2016 Jul; 20(1):208. PubMed ID: 27374027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiogenic shock: Inotropes and vasopressors.
    Amado J; Gago P; Santos W; Mimoso J; de Jesus I
    Rev Port Cardiol; 2016 Dec; 35(12):681-695. PubMed ID: 27836218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressors in Sepsis.
    Colling KP; Banton KL; Beilman GJ
    Surg Infect (Larchmt); 2018; 19(2):202-207. PubMed ID: 29336676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
    Levy B; Buzon J; Kimmoun A
    Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressors and inotropes in the treatment of human septic shock: effect on innate immunity?
    Hartemink KJ; Groeneveld AB
    Inflammation; 2012 Feb; 35(1):206-13. PubMed ID: 21347606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of inotropes and vasopressor agents in critically ill patients.
    Bangash MN; Kong ML; Pearse RM
    Br J Pharmacol; 2012 Apr; 165(7):2015-33. PubMed ID: 21740415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic support in fluid-refractory pediatric septic shock.
    Ceneviva G; Paschall JA; Maffei F; Carcillo JA
    Pediatrics; 1998 Aug; 102(2):e19. PubMed ID: 9685464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pressors and inotropes.
    Kanter J; DeBlieux P
    Emerg Med Clin North Am; 2014 Nov; 32(4):823-34. PubMed ID: 25441037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.